Press Releases

All Releases
View Summary Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
Mar 8, 2010 		PDF 15.0 KB
View Summary Genomic Health Develops New Methods for Whole Genome Expression Analysis of Standard Pathology Tumor Specimens
Mar 1, 2010 		PDF 12.8 KB
View Summary Genomic Health Announces Analysis Reinforcing Clinical Utility of Oncotype DX(R) Breast Cancer Test in Asia Pacific Patient Population
Feb 26, 2010 		PDF 12.4 KB
View Summary Genomic Health Announces Year-End 2009 Financial Results
Feb 3, 2010 		PDF 20.7 KB
View Summary Genomic Health to Announce Fourth Quarter and Year-End 2009 Financial Results and Host Conference Call on Wednesday, February 3
Jan 27, 2010 		PDF 8.1 KB
View Summary Genomic Health Announces Worldwide Availability of the Oncotype DX(R) Colon Cancer Test
Jan 21, 2010 		PDF 13.6 KB
View Summary Genomic Health Announces Publication of Data Demonstrating that the Oncotype DX(R) Breast Cancer Test Significantly Influences Breast Cancer Treatment Decisions, While Increasing Physician Confidence and Patient Satisfaction
Jan 12, 2010 		PDF 19.9 KB
View Summary Genomic Health Announces Preliminary Q4 and 2009 Revenue
Jan 7, 2010 		PDF 9.0 KB
View Summary Genomic Health to Present at J.P. Morgan Healthcare Conference
Jan 4, 2010 		PDF 8.6 KB
View Summary Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX® in Multiple Breast Cancer Populations
Dec 15, 2009 		PDF 17.9 KB
View Summary Genomic Health Announces Results of Clinical Survey Showing Use of Oncotype DX(R) Changes Treatment Recommendations for Women With Lymph Node-Positive Breast Cancer, Leading to Overall Reduction in Chemotherapy
Dec 11, 2009 		PDF 12.6 KB
View Summary Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Dec 10, 2009 		PDF 13.8 KB
View Summary Genomic Health to Present Five New Studies at 32nd Annual San Antonio Breast Cancer Symposium
Dec 4, 2009 		PDF 13.3 KB
View Summary Genomic Health to Present at Piper Jaffray Health Care Conference
Nov 24, 2009 		PDF 8.6 KB
View Summary Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress
Nov 4, 2009 		PDF 18.5 KB
View Summary Genomic Health to Announce Third Quarter 2009 Financial Results and Host Conference Call on Wednesday, November 4, 2009
Oct 28, 2009 		PDF 10.2 KB
View Summary Genomic Health Announces Analyst Day Webcast Presentation to be Held on November 12, 2009
Oct 23, 2009 		PDF 9.0 KB
View Summary Genomic Health Announces Data Confirming Manual Microdissection of Biopsy Cavities Is Essential for Accurate Recurrence Risk Assessment in Early-Stage Breast Cancer Patients
Oct 9, 2009 		PDF 12.8 KB
View Summary Breastcancer.org Joins My Breast Cancer Coach to Provide Newly Diagnosed Patients With Online Personalized Treatment Information
Oct 8, 2009 		PDF 18.3 KB
View Summary Genomic Health to Present Studies at the American Society of Clinical Oncology 2009 Breast Cancer Symposium
Oct 6, 2009 		PDF 10.7 KB
Showing 1-20 of 149 Page: 1 2 3 ... 8  Next 20

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

  

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

 

Shareholder Tools

  

DISCLAIMER

The information in the press releases should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.


Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.